Ambu A/S (OTCMKTS:AMBBY - Get Free Report) shares were down 0.1% during trading on Thursday . The company traded as low as $17.06 and last traded at $17.06. Approximately 2,008 shares traded hands during mid-day trading, an increase of 311% from the average daily volume of 489 shares. The stock had previously closed at $17.07.
Ambu A/S Trading Down 5.3 %
The company has a debt-to-equity ratio of 0.08, a current ratio of 2.60 and a quick ratio of 1.47. The business's 50-day moving average is $18.14 and its 200 day moving average is $17.41. The firm has a market capitalization of $3.80 billion, a P/E ratio of 95.18 and a beta of 1.44.
Ambu A/S (OTCMKTS:AMBBY - Get Free Report) last issued its quarterly earnings results on Thursday, January 30th. The company reported $0.10 EPS for the quarter. Ambu A/S had a return on equity of 5.67% and a net margin of 5.69%.
Ambu A/S Company Profile
(
Get Free Report)
Ambu A/S develops, produces, and sells medical devices to hospitals, clinics, and rescue services worldwide. The company offers anaesthesia, and patient monitoring and diagnostics products. The company also offers endoscopy products, such as bronchoscopes, rhinolaryngoscopes, duodenoscopes, cystoscopes, and display units; and neurology products, including EEG and EMG electrodes, EMG guided injections, and intraoperative monitoring products.
Featured Articles
Before you consider Ambu A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ambu A/S wasn't on the list.
While Ambu A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.